The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kaprin A.D.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Apolikhin O.I.

N.A. Lopatkin Institute of Urology and Interventional Radiology, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

Alekseev B.Ia.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Sivkov A.V.

N.A. Lopatkin Institute of Urology and Interventional Radiology, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

Efremov G.D.

N.A. Lopatkin Institute of Urology and Interventional Radiology, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

Roshchin D.A.

N.A. Lopatkin Institute of Urology and Interventional Radiology, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

Mikhailenko D.S.

N.A. Lopatkin Institute of Urology and Interventional Radiology, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

Kachmazov A.A.

N.A. Lopatkin Institute of Urology and Interventional Radiology, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

Perepechin D.V.

Nauchno-issledovatel'skiĭ institut urologii, Moskva

Deryagina D.M.

N.A. Lopatkin Institute of Urology and Interventional Radiology, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

Clinical, morphological and molecular genetic prognostic factors for survival rates in non-muscle-invasive bladder cancer

Authors:

Kaprin A.D., Apolikhin O.I., Alekseev B.Ia., Sivkov A.V., Efremov G.D., Roshchin D.A., Mikhailenko D.S., Kachmazov A.A., Perepechin D.V., Deryagina D.M.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2018;7(1): 49‑54

DOI: 10.17116/onkolog20187149-54

Read: 1442 times

Download PDF (RU)
Contact the author
Table of contents

CLINICAL, MORPHOLOGICAL AND MOLECULAR GENETIC PROGNOSTIC FACTORS FOR SURVIVAL RATES IN NON-MUSCLE-INVASIVE BLADDER CANCER
CLINICAL, MORPHOLOGICAL AND MOLECULAR GENETIC PROGNOSTIC FACTORS FOR SURVIVAL RATES IN NON-MUSCLE-INVASIVE BLADDER CANCER

To cite this article:

Kaprin AD, Apolikhin OI, Alekseev BIa, et al. . Clinical, morphological and molecular genetic prognostic factors for survival rates in non-muscle-invasive bladder cancer. P.A. Herzen Journal of Oncology. 2018;7(1):49‑54. (In Russ.)
https://doi.org/10.17116/onkolog20187149-54

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Gender specificity of angiogenesis in patients with non-muscle inva­sive bladder cancer complicated by type 2 diabetes mellitus. Russian Journal of Preventive Medi­cine. 2025;(3):73-79
Abstract:

The review analyzes the prognostic value of the molecular markers FGFR3, p53, MDM2, survivin, caspase-3, Ki-67, and combinations thereof. Special attention is given to a promising area of investigating miRNAs (miRNA-222, miRNA-141, miRNA-155, miRNA-429 and others) in patients with non-muscle-invasive bladder cancer (BC). The existing prognostic models to predict its course have serious drawbacks. The identification of two types, such as luminal and basal, which are forms having various courses and aggressiveness, can be considered to be an important molecular discovery in the studies of BC. The molecular markers allow the two forms to be divided just at early stages. At the moment, a specific molecular marker that is ready for widespread clinical application cannot be identified. An alternative approach may be the use of a panel of tumor markers. Such a marker/diagnostic panel should be sought because the stratification of patients for the most accurate prognosis of the tumor process is the basis for choosing an individual treatment option.

Keywords:

non-muscle-invasive bladder cancer
molecular genetic markers
luminal
basal bladder cancer

Authors:

Kaprin A.D.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Apolikhin O.I.

N.A. Lopatkin Institute of Urology and Interventional Radiology, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

Alekseev B.Ia.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Sivkov A.V.

N.A. Lopatkin Institute of Urology and Interventional Radiology, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

Efremov G.D.

N.A. Lopatkin Institute of Urology and Interventional Radiology, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

Roshchin D.A.

N.A. Lopatkin Institute of Urology and Interventional Radiology, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

Mikhailenko D.S.

N.A. Lopatkin Institute of Urology and Interventional Radiology, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

Kachmazov A.A.

N.A. Lopatkin Institute of Urology and Interventional Radiology, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

Perepechin D.V.

Nauchno-issledovatel'skiĭ institut urologii, Moskva

Deryagina D.M.

N.A. Lopatkin Institute of Urology and Interventional Radiology, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

Close metadata

References:

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87-108. https://doi.org/10.3322/caac.21262
  2. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466-465. https://doi.org/10.1016/j.eururo.2005.12.031
  3. Lammers RJ, Palou J, Witjes WP, Janzing-Pastors MH, Caris CT, Witjes JA. Comparison of expected treatment outcomes, obtained using risk models and international guidelines, with observed treatment outcomes in a Dutch cohort of patients with non-muscle-invasive bladder cancer treated with intravesical chemotherapy. BJU Int. 2014;114(2):193-201. https://doi.org/10.1111/bju.12495
  4. Dadhania V, Zhang M, Zhang L, Bondaruk J, Majewski T, Siefker-Radtke A, Guo CC, Dinney C, Cogdell DE, Zhang S, Lee S, Lee JG, Weinstein JN, Baggerly K, McConkey D, Czerniak B. Meta-analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use. EBioMedicine. 2016;12:105-17. https://doi.org/10.1016/j.ebiom.2016.08.036
  5. Wang QY, Zhao Y, Zhang R. The role of mutations and overexpression of the fibroblast growth factor receptor-3 in bladder cancer. Minerva Med. 2015;106(6):333-337.
  6. Foth M, Ahmad I, van Rhijn BW, van der Kwast T, Bergman AM, King L, Ridgway R, Leung HY, Fraser S, Sansom OJ, Iwata T. Fibroblast growth factor receptor 3 activation plays a causative role in urothelial cancer pathogenesis in cooperation with Pten loss in mice. J Pathol. 2014;233(2):148-158. https://doi.org/10.1002/path.4334
  7. Tomlinson DC, Baldo O, Harnden P, Knowles MA. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol. 2007;213(1):91-98.
  8. Zieger K, Dyrskjøt L, Wiuf C, Jensen JL, Andersen CL, Jensen KM, Ørntoft TF. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors. Clin Cancer Res. 2005;11(21):7709-77019.
  9. Smal MP, Rolevich AI, Polyakov SL, Krasny SA, Goncharova RI. FGFR3 and TP53 mutations in a prospective cohort of Belarusian bladder cancer patients. Exp Oncol. 2014;36(4):246-251.
  10. Kehinde EO, Al-Maghrebi M, Anim JT, Kapila K, George SS, Al-Juwaiser A, Memon A. The significance of epidermal growth factor receptor and survivin expression in bladder cancer tissue and urine cytology of patients with transiyional cell carcinoma of the urinary bladder. East Afr Med J. 2013;90(1):19-27.
  11. Kim WT, Kim J, Yan C, Jeong P, Choi SY, Lee OJ, Kim WJ. S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy. Ann Oncol. 2014;25(5):974-979. https://doi.org/10.1093/annonc/mdu037
  12. Nakopoulou L, Constantinides C, Papandropoulos J, Theodoropoulos G, Tzonou A, Giannopoulos A, Zervas A, Dimopoulos C. Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy. Urology. 1995;46(3):334-340.
  13. Saidi S, Popov Z, Stavridis S, Janevska V, Panov S. Digital quantitative immunofluorescent detection of p53 protein in urinary bladder cancer tissue samples. Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2013;34(1):167-174.
  14. Salinas-Sánchez AS, Lorenzo-Romero JG, Giménez-Bachs JM, Sánchez-Sánchez F, Donate-Moreno MJ, Rubio-Del-Campo A, Hernández-Millán IR, Segura-Martín M, Atienzar-Tobarra M, Escribano-Martínez J. Implications of p53 gene mutations on patient survival in transitional cell carcinoma of the bladder: a long-term study. Urol Oncol. 2008;26(6):620-626. https://doi.org/10.1016/j.urolonc.2007.07.011
  15. Lin HY, Huang CH, Yu TJ, Wu WJ, Yang MC, Lung FW. p53 codon 72 polymorphism as a progression index for bladder cancer. Oncol Rep. 2012;27(4):1193-1199. https://doi.org/10.3892/or.2011.1610
  16. Warfel NA, El-Deiry WS. p21WAF1 and tumourigenesis: 20 years after. Curr Opin Oncol. 2013;25(1):52-58. https://doi.org/10.1097/CCO.0b013e32835b639e
  17. Tang K, Wang C, Chen Z, Xu H, Ye Z. Clinicopathologic and prognostic significance of p21 (Cip1/Waf1) expression in bladder cancer. Int J Clin Exp Pathol. 2015;8(5):4999-5007.
  18. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004;119(5):591-602.
  19. Ding H, Dai Y, Ning Z, Fan N, Wang Z, Li P, Zhang L, Tao Y, Wang H. Murine double minute 2 SNP T309G polymorphism and urinary tract cancer risk: a meta-analysis. Medicine (Baltimore). 2016;95(12):e2941. https://doi.org/10.1097/MD.0000000000002941
  20. Hitzenbichler F, Stoehr CG, Rogenhofer M, Wieland WF, Ruemmele P, Hartmann A, Stoehr R. Mdm2 SNP309 G-variant is associated with invasive growth of human urinary bladder cancer. Pathobiology. 2014;81(2):53-59. https://doi.org/10.1159/000355976
  21. Liu G, Jiang D, Shen S, Yu L. Murine double minute 2 promoter SNP309 polymorphism and prostate cancer risk: a meta-analysis. Int J Urol. 2012;19(10):914-920. https://doi.org/10.1111/j.1442-2042.2012.03067.x
  22. Xie L, Sun Y, Chen T, Tian D, Li Y, Zhang Y, Ding N, Shen Z, Xu H, Nian X, Sha N, Han R, Hu H, Wu C. Association between MDM2 SNP309 T>G polymorphism and the risk of bladder cancer: new data in a Chinese population and an updated meta-analysis. Onco Targets Ther. 2015;8:3679-3690. https://doi.org/10.2147/OTT.S95353
  23. Wang J, Zhang X, Wei P, Zhang J, Niu Y, Kang N, Zhang Y, Zhang W, Xing N. Livin, Survivin and Caspase 3 as early recurrence markers in non-muscle-invasive bladder cancer. World J Urol. 2014;32(6):1477-1484. https://doi.org/10.1007/s00345-014-1246-0
  24. Lv S, Turlova E, Zhao S, Kang H, Han M, Sun HS. Prognostic and clinicopathological significance of survivin expression in bladder cancer patients: a meta-analysis. Tumour Biol. 2014;35(2):1565-1574. https://doi.org/10.1007/s13277-013-1216-y
  25. Wang J, Zhang X, Wei P, Zhang J, Niu Y, Kang N, Zhang Y, Zhang W, Xing N. Livin, Survivin and Caspase 3 as early recurrence markers in non-muscle-invasive bladder cancer. World J Urol. 2014;32(6):1477-1484. https://doi.org/10.1007/s00345-014-1246-0
  26. Luo Y, Zhang X, Mo M, Tan Z, Huang L, Zhou H, Wang C, Wei F, Qiu X, He R, Chen G. High Ki-67 immunohistochemical reactivity correlates with poor prognosis in bladder carcinoma: a comprehensive meta-analysis with 13,053 patients involved. Medicine (Baltimore). 2016;95(15):e3337. https://doi.org/10.1097/MD.0000000000003337
  27. Shariat SF, Bolenz C, Godoy G, Fradet Y, Ashfaq R, Karakiewicz PI, Isbarn H, Jeldres C, Rigaud J, Sagalowsky AI, Lotan Y. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. J Urol. 2009;182(1):78-84. https://doi.org/10.1016/j.juro.2009.02.125
  28. Shariat SF, Passoni N, Bagrodia A, Rachakonda V, Xylinas E, Robinson B, Kapur P, Sagalowsky AI, Lotan Y. Prospective evaluation of a preoperative biomarker panel for prediction of upstaging at radical cystectomy. BJU Int. 2014;113(1):70-76. https://doi.org/10.1111/bju.12343
  29. Lotan Y, Bagrodia A, Passoni N, Rachakonda V, Kapur P, Arriaga Y, Bolenz C, Margulis V, Raj GV, Sagalowsky AI, Shariat SF. Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy. Eur Urol. 2013;64(3):465-471. https://doi.org/10.1016/j.eururo.2013.03.043
  30. Huang J, Ma X, Chen X, Liu X, Zhang B, Minmin L, Nie W, Zhang L, Liu L. Microvessel density as a prognostic factor in bladder cancer: a systematic review of literature and meta-analysis. Cancer Biomark. 2014;14(6):505-514. https://doi.org/10.3233/CBM-140417
  31. Ajili F, Kacem M, Tounsi H, Darouiche A, Enayfer E, Chebi M, Manai M, Boubaker S. Prognostic impact of angiogenesis in nonmuscle invasive bladder cancer as defined by microvessel density after immunohistochemical staining for CD34. Ultrastruct Pathol. 2012;36(5):336-342. https://doi.org/10.3109/01913123.2012.672847
  32. Marzioni D, Lorenzi T, Mazzucchelli R, Capparuccia L, Morroni M, Fiorini R, Bracalenti C, Catalano A, David G, Castellucci M, Muzzonigro G, Montironi R. Expression of basic fibroblast growth factor, its receptors and syndecans in bladder cancer. Int J Immunopathol Pharmacol. 2009;22(3):627-638.
  33. Szarvas T, Jäger T, Laszlo V, Kramer G, Klingler HC, vom Dorp F, Romics I, Ergün S, Rübben H. Circulating angiostatin, bFGF, and Tie2/TEK levels and their prognostic impact in bladder cancer. Urology. 2012;80(3):737.e13-у18. https://doi.org/10.1016/j.urology.2012.03.023
  34. Lajin B, Alachkar A. The NQO1 polymorphism C609T (Pro187Ser) and cancer susceptibility: a comprehensive meta-analysis. Br J Cancer. 2013;109(5):1325-1337. https://doi.org/10.1038/bjc.2013.357
  35. Guo ZJ, Feng CL. The NQO1 rs1800566 polymorphism and risk of bladder cancer: evidence from 6,169 subjects. Asian Pac J Cancer Prev. 2012;13(12):6343-6348.
  36. Zhang DQ, Zhou CK, Jiang XW, Chen J, Shi BK. Increased expression of miR-222 is associated with poor prognosis in bladder cancer. World J Surg Oncol. 2014;12:241. https://doi.org/10.1186/1477-7819-12-241
  37. Puerta-Gil P, García-Baquero R, Jia AY, Ocaña S, Alvarez-Múgica M, Alvarez-Ossorio JL, Cordon-Cardo C, Cava F, Sánchez-Carbayo M. miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer. Am J Pathol. 2012;180(5):1808-1815. https://doi.org/10.1016/j.ajpath.2012.01.034
  38. Veerla S, Lindgren D, Kvist A, Frigyesi A, Staaf J, Persson H, Liedberg F, Chebil G, Gudjonsson S, Borg A, Månsson W, Rovira C, Höglund M. MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int J Cancer. 2009;124(9):2236-2242. https://doi.org/10.1002/ijc.24183
  39. Yu B, Liu X, Chang H. MicroRNA-143 inhibits colorectal cancer cell proliferation by targeting MMP7. Minerva Med. 2017;108(1):13-19. https://doi.org/10.23736/S0026-4806.16.04651-6
  40. Liu X, Gong J, Xu B. miR-143 down-regulates TLR2 expression in hepatoma cells and inhibits hepatoma cell proliferation and invasion. Int J Clin Exp Pathol. 2015;8(10):12738-12747.
  41. Wang H, Li Q, Niu X, Wang G, Zheng S, Fu G, Wang Z. miR-143 inhibits bladder cancer cell proliferation and enhances their sensitivity to gemcitabine by repressing IGF-1R signaling. Oncol Lett. 2017;13(1):435-440. https://doi.org/10.3892/ol.2016.5388
  42. Wu J, Huang Q, Meng D, Huang M, Li C, Qin T. A functional rs353293 polymorphism in the promoter of miR-143/145 is associated with a reduced risk of bladder cancer. PLoS One. 2016;11(7):e0159115. https://doi.org/10.1371/journal.pone.0159115
  43. Dyrskjøt L, Ostenfeld MS, Bramsen JB, Silahtaroglu AN, Lamy P, Ramanathan R, Fristrup N, Jensen JL, Andersen CL, Zieger K, Kauppinen S, Ulhøi BP, Kjems J, Borre M, Orntoft TF. Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res. 2009;69(11):4851-4860. https://doi.org/10.1158/0008-5472.CAN-08-4043
  44. Ichimi T, Enokida H, Okuno Y, Kunimoto R, Chiyomaru T, Kawamoto K, Kawahara K, Toki K, Kawakami K, Nishiyama K, Tsujimoto G, Nakagawa M, Seki N. Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer. 2009;125(2):345-352. https://doi.org/10.1002/ijc.24390
  45. Adam L, Wszolek MF, Liu CG, Jing W, Diao L, Zien A, Zhang JD, Jackson D, Dinney CP. Plasma microRNA profiles for bladder cancer detection. Urol Oncol. 2013;31(8):1701-1708. https://doi.org/10.1016/j.urolonc.2012.06.010
  46. Allegra A, Alonci A, Campo S, Penna G, Petrungaro A, Gerace D, Musolino C. Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (review). Int J Oncol. 2012;41(6):1897-1912. https://doi.org/10.3892/ijo.2012.1647
  47. Guancial EA, Bellmunt J, Yeh S, Rosenberg JE, Berman DM. The evolving understanding of microRNA in bladder cancer. Urol Oncol. 2014;32(1):41.e31-40. https://doi.org/10.1016/j.urolonc.2013.04.014
  48. Homami A, Ghazi F. MicroRNAs as biomarkers associated with bladder cancer. Med J Islam Repub Iran. 2016;30:475.
  49. Mikhailenko DS, Nemtsova MV. Point somatic mutations in bladder cancer: key carcinogenesis events, diagnostic markers and therapeutic targets. Urologiya. 2016;(1):100-5. (In Russ.)
  50. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315-322. https://doi.org/10.1038/nature12965
  51. Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev. 2015;15:25-41. https://doi.org/10.1038/nrc3817
  52. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O’Donnell PH, Balmanoukian A, Loriot Y, Srinivas S, Retz MM, Grivas P, Joseph RW, Galsky MD, Fleming MT, Petrylak DP, Perez-Gracia JL, Burris HA, Castellano D, Canil C, Bellmunt J, Bajorin D, Nickles D, Bourgon R, Frampton GM, Cui N, Mariathasan S, Abidoye O, Fine GD, Dreicer R. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909-1920. https://doi.org/10.1016/S0140-6736(16)00561-4
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.